Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer.

ABSTRACT:

Background

Patient Derived Organoids (PDOs) emerged as the best technology to develop ex vivo tumor avatars. Whether drug testing on PDOs to identify efficient therapies will bring clinical utility by improving patient survival remains unclear. To test this hypothesis in the frame of clinical trials, PDO technology faces three main challenges to be implemented in routine clinical practices: i) generating PDOs with a limited amount of tumor material; ii) testing a wide panel of anti-cancer drugs; and iii) obtaining results within a time frame compatible with patient disease management. We aimed to address these challenges in a prospective study in patients with colorectal cancer (CRC).

Methods

Fresh surgical or core needle biopsies were obtained from patients with CRC. PDOs w

SUBMITTER: Cartry J 

PROVIDER: S-EPMC10598932 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature